Preview

PDF Pending copyright assessment - Request a copy 71Kb

Vulvovaginal candidiasis is a common infection among women and is associated with significant morbidity and health care costs. Approximately 75% of women will receive a diagnosis of vulvovaginal candidiasis at least once, and of those, about 50% will have a recurrence.1 Recent therapy with broad-spectrum antibiotics is a risk factor, presumably because of the elimination of the protective vaginal flora, especially lactobacilli. Hence, there is a rationale for replacing these microorganisms to treat, or supplementing the microorganisms to prevent, antibiotic-associated vulvovaginal candidiasis.

Probiotics are defined as live microorganisms that confer a health benefit on the host. Many different strains are available, including Lactobacillus acidophilus (now reuteri), L. fermentum (now casei), L. rhamnosus, L. bulgaricus, L. delbrueckii, Bifidobacterium longum and Saccharomyces boulardii. Probiotics are commonly used and recommended for vulvovaginitis, normally caused by Candida albicans, that develops after antibiotic treatment.3 In one Australian study, 40% of 751 women with a history of vulvovaginitis had used yoghurt or lactobacillus orally or vaginally in an attempt to prevent antibiotic-associated vulvovaginitis. In the same study, 23% of women surveyed who had taken antibiotics in the previous month had experienced symptoms of vulvovaginitis. Anecdotally, many pharmacists and pharmacy assistants recommend the use of probiotics for women who are dispensed antibiotics. Some pharmacies use point of sale notifications to remind staff to recommend probiotics to women if antibiotics are dispensed; other strategies include the use of stickers placed on antibiotic packs to recommend probiotics, even specific brands of probiotics.

Item Type:	Professional, Non Refereed Article
Keywords:	Vulvovaginal candidiasis, probiotics, antibiotics, health care costs
Research Division:	Medical and Health Sciences
Research Group:	Public Health and Health Services
Research Field:	Public Health and Health Services not elsewhere classified
Objective Division:	Health
Objective Group:	Public Health (excl. Specific Population Health)
Objective Field:	Preventive Medicine
UTAS Author:	Bereznicki, LRE (Professor Luke Bereznicki)
UTAS Author:	Jackson, SL (Dr Shane Jackson)
UTAS Author:	Peterson, GM (Professor Gregory Peterson)
ID Code:	44563
Year Published:	2007
Deposited By:	Pharmacy
Deposited On:	2007-06-07
Last Modified:	2012-10-23
Downloads:	3 View Download Statistics